Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW BRUNSWICK, N.J., Jan. 26, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. "Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing...

Johnson & Johnson Reports 2020 Fourth-Quarter And Full Year Results

Johnson & Johnson on Tuesday posted an 8.3% rise in quarterly sales and said it would share details from its keenly watched coronavirus vaccine trial soon, as the healthcare conglomerate races to develop a potential single-dose vaccine for COVID-19.

Johnson & Johnson quarterly sales rise 8.3%, sees vaccine data "soon"

The drug and and consumer products company reported adjusted earnings of $1.86 per share, higher than the $1.82 expected in a survey of analysts by Refinitiv.

J&J beats fourth-quarter earnings expectations, will release Covid vaccine data 'soon'

Should You Buy Johnson & Johnson Stock Before Its Big Coronavirus Vaccine News?

Johnson & Johnson's Covid-19 vaccine is one of the most closely watched shots against the novel coronavirus, given that it is backed by one of the world's largest pharma companies and is expected to require only a single dose. Here's a quick rundown of the expected timeline for the vaccine's.

Johnson & Johnson's Vaccine Updates: When Will The Shot Be Available For Use?

J&J Snack Foods Corp. JJSF shares dropped after the snack food company's quarterly earnings fell short of Wall Street estimates. J&J Snack shares fell 14% after hours, following a 2.5% rise to close the session at $156.89.

J&J Snack stock drops 14% as earnings miss Street expectations

GameStop

McDonald's

Clorox

GameStop, Clorox, Johnson & Johnson and McDonald's were our top stock trades for Tuesday. Now, let's look at the charts after a busy day.

4 Top Stock Trades for Tuesday: GME, CLX, JNJ, MCD

Johnson & Johnson is expected soon to release test results for its coronavirus vaccine in a move that could rock vaccine stocks Pfizer and Moderna. Pfizer and Moderna have authorized drugs.

Covid Vaccines: Here's What J&J Has To Do To Undercut Pfizer, Moderna

After Moderna and Merck's news, the path for a swift vaccine rollout looks a bit rockier than it did last week.

The Market Is Looking to Johnson & Johnson for Hope After a Grim Morning

Shares of Johnson & Johnson were up 0.9% in trading on Monday, as the company nears the anticipated disclosure of interim results from a late-stage clinical trial evaluating its single-dose COVID-19 vaccine candidate. J&J said in mid-December it expects to share findings from the Phase 3 trial by the end of January, which would it the third company testing coronavirus vaccines in the U.S. to announce results from a closely watched Phase 3 trial.

J&J may share findings from Phase 3 vaccine trial this week

Despite a 45% rise since the March 23 lows of last year, at the current price of around $161 per share we believe that pharmaceuticals bellwether, Johnson & Johnson, looks attractive and it can see more upside from the current levels. JNJ stock has rallied from $111 to $161, underperforming.

Should You Buy Johnson & Johnson Stock At $160?

CRISPR Therapeutics

Editas Medicine

SPDR S&P 500 ETF Trust

Vertex Pharmaceuticals

Vanguard Total Stock Market ETF

With a nest egg this sizable, you'll need to find more than one place to put your money so it keeps growing.

Where to Invest $1 Million Right Now

Apple

Amgen

Disney

Dow Inc

Home Depot

Merck

NIKE

QuidelOrtho Corp

Travelers

Vista Outdoor

Two new breakout stocks for Week 4 of 2021 with better than 10% short-term upside potential. This past week 3 out of 4 stocks gained over 10% in a short trading week but gave back most of their gains closing for an avg loss of -4.1%. 2021 MDA portfolio returns are on record pace up +36.3% in the first three weeks with 10 out of 12 picks gaining more than 10% in less than a week.

Week 4 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge

The first single-dose COVID-19 vaccine could get emergency approval in just two weeks, Dr. Anthony Fauci said late Friday.

The New York Post: Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks

AstraZeneca

Bank of America

BioNTech SE

Moderna

Pfizer

Moderna and Pfizer/BioNTech should rake in similar levels of revenue for their vaccines.

Top Coronavirus Vaccine Makers Will Earn Up to $23 Billion in Revenue This Year, Says New Analysis

J&J's (JNJ) Pharma segment is expected to have performed above market while continued procedure stabilization is expected to have benefited the Medical Devices segment in the fourth quarter.

J&J (JNJ) to Get the Ball Rolling for Pharma Q4 Earnings

More data on the Johnson & Johnson vaccine, expected in the coming days, will have ripple effects across the market.

Johnson & Johnson Aims for 100 Million Vaccine Doses by Spring. The Stock Market Is Counting on It.

Johnson & Johnson hopes to have enough COVID-19 vaccines for 100 million Americans by April as the feds ramp up nationwide inoculation efforts, a company official says.

Johnson & Johnson eyes 100M COVID-19 vaccines for US by April

Less may be more when it comes to rolling out a coronavirus vaccine. Johnson & Johnson's one-dose vaccine could have an edge over Pfizer and Moderna's shots– even though it's still several weeks away from approval in the US, Wall Street analysts told The Post.

One-shot COVID-19 vaccine may give Johnson & Johnson an edge

Bloomberg reports that Johnson & Johnson (NYSE: JNJ) is on track to analyze data from its late-stage single-dose COVID-19 vaccine trial. Dr. Anthony Fauci said in his remarks at the White House that JNJ has enough data to begin analysis in a week or two.

Johnson & Johnson Could Have 100 Million COVID-19 Vaccines By April, Board Member McClellan Says

Cardinal Health

Kimberly-Clark

The lowest yield on this list is 2.5% and well above what the average S&P 500 stock pays today.

3 Cheap Dividend Aristocrats to Buy Right Now

Algonquin Power & Utilities

Brookfield Renewable Partners

CVS Health

General Dynamics

Lockheed Martin

Microsoft

TC Energy

Waste Connections

2020, for our investments, was a good year. We kept the cash from the Emera sale for emergency funds during the first lockdown when we weren't working.

2020 Portfolio Activity Summary And 2021 Target

A J&J board member said “if the clinical trial works out,” the company could significantly increase the nation's Covid vaccine supply availability.

News for Johnson & Johnson Stock (JNJ)